Glucagon agonist how to use in obesity
Reading File
Finding Sources
Finding Sources
Searching PubMed
glucagon receptor agonist obesity treatment
Searching the Web
glucagon agonist obesity treatment 2025 GLP-1 dual triple agonist
Reading File
Reading File
Reading File
Reading Article
Reading File
Reading File
I now have comprehensive information to provide a thorough, well-structured answer. Let me synthesize everything.
Glucagon-Related Agonists in Obesity Management
Clarifying the Terminology
"Glucagon agonist" in the obesity context most commonly refers to GLP-1 (glucagon-like peptide-1) receptor agonists — peptides derived from the proglucagon gene, like glucagon itself, but acting on a distinct receptor. The term also increasingly covers dual and triple agonists that co-target the glucagon receptor alongside GLP-1 and GIP receptors. The pure glucagon receptor agonist as a stand-alone obesity agent is still experimental.
1. GLP-1 Receptor Agonists (GLP-1 RAs)
Mechanism
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food. GLP-1 RAs reduce body weight by:
- Slowing gastric emptying → prolonged satiety
- Acting on hypothalamic appetite-regulation centers → reduced hunger
- Stimulating glucose-dependent insulin secretion + inhibiting glucagon secretion
- Increasing energy expenditure
FDA-Approved Agents for Obesity
| Drug | Receptor | Route | Dosing | Placebo-Subtracted Weight Loss |
|---|---|---|---|---|
| Liraglutide (Saxenda) | GLP-1 | SC once daily | Start 0.6 mg/day → titrate to 3 mg/day over 5 weeks | ~5.4% |
| Semaglutide (Wegovy) | GLP-1 | SC once weekly | Start 0.25 mg/wk → titrate over 16–20 weeks to 2.4 mg/wk | ~12.5% |
| Tirzepatide (Zepbound) | GLP-1 + GIP (dual) | SC once weekly | Start 2.5 mg/wk → titrate every 4 weeks to max 15 mg/wk | ~17.8% |
Data from Harrison's 22E (2025), Sabiston Textbook of Surgery, and SURMOUNT/STEP trials
2. How to Use Each Agent
Liraglutide 3 mg (Saxenda)
- Indication: BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity
- Dose escalation (SC, once daily):
- Week 1: 0.6 mg/day
- Week 2: 1.2 mg/day
- Week 3: 1.8 mg/day
- Week 4: 2.4 mg/day
- Week 5 onward: 3.0 mg/day (maintenance)
- Expected weight loss: ~6% above placebo at 56 weeks
- Discontinue if < 4% weight loss by week 16
Semaglutide 2.4 mg (Wegovy)
- Indication: Same BMI criteria as liraglutide
- Dose escalation (SC, once weekly):
- Weeks 1–4: 0.25 mg/wk
- Weeks 5–8: 0.5 mg/wk
- Weeks 9–12: 1.0 mg/wk
- Weeks 13–16: 1.7 mg/wk
- Week 17+: 2.4 mg/wk (maintenance)
- Oral semaglutide (Rybelsus, 3→7→14 mg/day) is also available for T2DM and has weight-loss benefit, though lower than injectable
- Expected weight loss: ~15% total body weight (STEP trials); SELECT trial showed 20% reduction in MACE in overweight/obese without diabetes
- Discontinue if < 5% weight loss by week 16
Tirzepatide (Zepbound) — Dual GIP/GLP-1
- Indication: Same BMI criteria; also approved for obstructive sleep apnea with obesity and HFpEF with obesity
- Dose escalation (SC, once weekly):
- Weeks 1–4: 2.5 mg/wk
- Weeks 5–8: 5 mg/wk
- Weeks 9–12: 7.5 mg/wk
- Weeks 13–16: 10 mg/wk
- Weeks 17–20: 12.5 mg/wk
- Week 21+: 15 mg/wk (maximum)
- Expected weight loss: ~20–22% total body weight (SURMOUNT-1); up to 24% when continued after initial period (SURMOUNT-4)
- The GIP component adds synergistic insulin sensitization and further appetite suppression beyond GLP-1 alone
3. The Pure Glucagon Receptor Angle: Dual & Triple Agonists
Glucagon receptor co-agonism is specifically being incorporated into next-generation agents because glucagon:
- Stimulates hepatic fat oxidation and thermogenesis
- Increases energy expenditure (brown adipose tissue activation)
- Promotes hepatic lipid clearance
Retatrutide (Investigational — Phase 2/3)
A triple agonist (GIP + GLP-1 + glucagon receptor):
- Phase 2 RCT (NEJM 2023, PMID 37366315) showed 24.2% weight loss at 48 weeks with 12 mg dose
- 100% of participants on 8–12 mg achieved ≥5% weight loss; 83–93% achieved ≥15%
- SC once weekly; dose-dependent GI side effects (nausea, vomiting) were partially mitigated with lower starting dose (2 mg)
- Phase 3 trials ongoing
4. Key Contraindications (All GLP-1 Class)
- Personal or family history of medullary thyroid carcinoma
- MEN type 2 syndrome
- History of pancreatitis (caution)
- Pregnancy
- Severe renal or hepatic impairment (dose-dependent consideration)
5. Common Adverse Effects
- GI dominant: Nausea, vomiting, diarrhea, constipation, dyspepsia — most prominent during dose escalation; resolve with slower titration
- Dose reduction or slowing titration recommended if intolerable GI effects
- Retatrutide/triple agonists additionally showed dose-dependent heart rate increase (peaked at 24 weeks, then declined)
6. Practical Clinical Guidance
| Scenario | Preferred Agent |
|---|---|
| Max weight loss needed | Tirzepatide (or retatrutide when available) |
| Obesity + T2DM | Tirzepatide or semaglutide (dual benefit) |
| Obesity + established CVD | Semaglutide (SELECT trial CV benefit proven) |
| Obesity + OSA | Tirzepatide (NEJM 2024, PMID 38912654) |
| Obesity + HFpEF | Tirzepatide (NEJM 2025, PMID 39555826) |
| Post-bariatric surgery with weight regain | Semaglutide preferred over liraglutide (meta-analysis: ~10% additional loss) |
| Bridge to bariatric surgery (high BMI) | Any GLP-1 RA to reduce surgical risk |
⚠️ Important: Weight regain occurs rapidly on discontinuation — approximately two-thirds of lost weight returns within 1 year of stopping. Treatment should be considered long-term/indefinite, similar to antihypertensives or statins. (Meta-analysis, Obes Rev 2025, PMID 40186344)
Summary
The "glucagon agonist" family in obesity spans a spectrum from pure GLP-1 RAs (liraglutide, semaglutide) to dual GIP/GLP-1 agonists (tirzepatide) to triple GIP/GLP-1/glucagon agonists (retatrutide — investigational). The progression up this spectrum delivers progressively greater weight loss, largely because co-agonism at the glucagon receptor adds thermogenic and hepatic fat-burning effects to the appetite suppression of GLP-1. All agents require gradual dose escalation, SC administration (except oral semaglutide), and should be paired with lifestyle modification.
This is a shared conversation. Sign in to Orris to start your own chat.